
Halozyme Therapeutics has announced it is to cull its workforce by more than half in the wake of the news …

Takeda has announced it is divesting a portfolio of its over-the-counter (OTC) and prescription drug products to Stada for a …

The FDA has authorised the availability of Sandoz’s Ziextenzo (pegfilgrastim-bmez), a biosimilar version of Amgen’s Neulasta, it has emerged. The …

Sanofi’s quadrivalent influenza vaccine Fluzone High Dose has secured FDA approval in adult patients over the age of 65 for …

Liz Lewis, Head of Global Oncology Patient Value, Policy and Access at Takeda Oncology, discusses the importance and challenges of …

RedHill Biopharma is celebrating after the FDA chose to award marketing authorisation to Talicia (omeprazole magnesium, amoxicillin and rifabutin) for …

With the release of its Q3 financial results, AbbVie confirmed that international revenues for its blockbuster therapy Humira (adalimumab) – …

The US FDA could be set to receive its next long-term Commissioner after the White House revealed President Donald Trump’s …

Shanghai Green Valley Pharmaceuticals has announced that its therapy Oligomannate (GV-971) has secured marketing approval from China’s National Medical Products Administration (NMPA) …

Sanofi took the opportunity at the International Society for Pediatric and Adolescent Diabetes 45th Annual Conference in Boston, Massachusetts to …

Elderly patients are being put at risk by prescriptions for drugs which have not been properly tested in their age …

A new report has revealed that GPs in England are writing fewer prescriptions for antibiotics, but this has done little …

Amgen has signed an agreement with Chinese biotech BeiGene to acquire a 20.5% stake in the latter, in a bid …

Novartis has announced new data drawn from a trial pitting Cosentyx (secukinumab) in head-to-head competition with AbbVie’s Humira (adalimumab) – …

With mergers and acquisitions back in full swing after a period of drought, Alec Burnside (Partner) and Delphine Strohl (Associate) …

AbbVie has unveiled new Phase 3 data on two doses of its JAK inhibitor Rinvoq (upadacitinib), showing that the therapy …

Catalyst Pharmaceuticals has made it known that its lead product Firdapse (Amifampridine Phosphate) fell short of its primary endpoint in …

The trio of Galapagos, MorphoSys and Novartis Pharma has revealed that all further development of its MOR106 drug candidate for …

David Eatwell, Executive Vice President and Chief Financial Officer at Genmab, has announced his intention to step down from the …